Hepatitis C virus infection does not preclude standard breast cancer-directed therapy Journal Article
| Authors: | D'Angelo, S.; Deutscher, M.; Dickler, M.; Weinstock, D. |
| Article Title: | Hepatitis C virus infection does not preclude standard breast cancer-directed therapy |
| Abstract: | In the United States, over 3 million people are infected with hepatitis C virus (HCV), and over 200,000 women develop breast cancer annually. Yet, no published studies have investigated the tolerability of breast cancer- directed therapy among women with HCV infection. We reviewed records at Memorial Sloan-Kettering Cancer Center and identified 35 patients with chronic HCV infection who were treated for breast cancer between the years 1991 and 2005. One (2.9%) of 35 also had chronic hepatitis B virus infection. There were no complications related to HCV infection during or after surgery or radiation therapy. A total of 29 (82.9%) of the 35 patients received chemotherapy for breast cancer. Of the 29, only 4 required chemotherapy delays or adjustments in dosing because of HCV infection. In conclusion, breast cancer therapy was well tolerated among women with HCV infection. Considering the paucity of complications, routine screening for HCV infection is not warranted among women with breast cancer and no defined risk factors for HCV infection. |
| Keywords: | cancer chemotherapy; clinical article; treatment outcome; cancer surgery; survival rate; drug tolerability; neutropenia; cirrhosis; bevacizumab; doxorubicin; fluorouracil; ascites; cancer combination chemotherapy; drug withdrawal; hepatitis b; hepatitis c; liver cirrhosis; multimodality cancer therapy; side effect; antineoplastic agents; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; cancer adjuvant therapy; cancer radiotherapy; combined modality therapy; methotrexate; cancer staging; antineoplastic agent; breast cancer; etoposide; thrombocytopenia; cyclophosphamide; breast neoplasms; cancer therapy; risk factor; physiology; virology; docetaxel; alanine aminotransferase blood level; alanine aminotransferase; drug fatality; cancer center; virus rna; breast tumor; therapy delay; tamoxifen; jaundice; epirubicin; virus infection; letrozole; liver function test; trastuzumab; anastrozole; navelbine; recombinant granulocyte colony stimulating factor; drug substitution; hepatitis b virus; hepatitis c virus; medical assistant; rna virus; hepacivirus |
| Journal Title: | Clinical Breast Cancer |
| Volume: | 9 |
| Issue: | 1 |
| ISSN: | 1526-8209 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2009-02-01 |
| Start Page: | 51 |
| End Page: | 52 |
| Language: | English |
| DOI: | 10.3816/CBC.2009.n.009 |
| PUBMED: | 19299241 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "CODEN: CBCLB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work